Phase I CD22 CAR T-cell trial updates

被引：3

作者：

Shah, Nirali N. ^{[1
]}

Shalabi, Haneen ^{[1
]}

Yates, Bonnie ^{[1
]}

Yuan, Constance ^{[1
]}

Qin, Haiying ^{[1
]}

Ombrello, Amanda ^{[2
]}

Wang, Hao-Wei ^{[1
]}

Hoffman, Leah ^{[1
]}

Minh Tran ^{[3
]}

Panch, Sandhya ^{[3
]}

Stetler-Stevenson, Maryalice ^{[1
]}

Jin, Jianjian ^{[1
]}

Mackall, Crystal ^{[4
]}

Highfill, Steve ^{[3
]}

Stroncek, David ^{[3
]}

Fry, Terry J. ^{[5
]}

机构：

[1] NCI, Bethesda, MD 20892 USA

[2] NHGRI, Bethesda, MD 20892 USA

[3] NIH, Bldg 10, Bethesda, MD 20892 USA

[4] Stanford, Palo Alto, CA USA

[5] Univ Colorado, Childrens Hosp Colorado, Denver, CO 80202 USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.SABCS18-LB-146

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB-146

引用

页数：4

共 50 条

[21] Upregulation of CD22 by Chidamide promotes CAR T cells functionality
Xin Yang
Qiuxia Yu
Hao Xu
Jianfeng Zhou
Scientific Reports, 11
[22] Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies
Hossain, Nasheed
Sahaf, Bita
Abramian, Matthew
Spiegel, Jay Y.
Kong, Katie
Kim, Stephen
Mavroukakis, Sharon
Oak, Jean
Natkunam, Yasodha
Meyer, Everett H.
Frank, Matthew J.
Feldman, Steven A.
Long, Steven R.
Qin, Haiying
Fry, Terry J.
Muffly, Lori S.
Mackall, Crystal L.
Miklos, David B.
BLOOD, 2018, 132
[23] Generation of a Highly Sensitive CD22 CAR
Kokalaki, Evangelia K.
Ma, Biao
Grothier, Thomas
Hazelton, Warren
Costu, Eren
Manzoor, Somayya
Jha, Ram
Thomas, Simon
Onuoha, Shimobi
Cordoba, Shaun P.
Pule, Martin
BLOOD, 2019, 134
[24] T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma
Wang, Jiachen
Shen, Kefeng
Mu, Wei
Li, Weigang
Zhang, Meilan
Zhang, Wei
Li, Zhe
Ge, Tong
Zhu, Zhoujie
Zhang, Shangkun
Chen, Caixia
Xing, Shugang
Zhu, Li
Chen, Liting
Wang, Na
Huang, Liang
Li, Dengju
Xiao, Min
Zhou, Jianfeng
FRONTIERS IN IMMUNOLOGY, 2022, 13
[25] Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation
Tuscano, J
Engel, P
Tedder, TF
Kehrl, JH
BLOOD, 1996, 87 (11) : 4723 - 4730
[26] Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
Huang, Lefu
Li, Jingjing
Yang, Junfang
Zhang, Xian
Zhang, Min
He, Jiujiang
Zhang, Gailing
Li, Wenqian
Wang, Hui
Li, Jianqiang
Lu, Peihua
CELLS, 2022, 11 (24)
[27] CAR T-Cell Therapy Updates in nursing management
Baer, Brittney
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2021, 25 (03) : 255 - 258
[28] HEMATOPOIETIC TOXICITIES AND COAGULOPATHY FOLLOWING CD22 CAR T-CELLS
Jess, Jennifer
Yates, Bonnie
Dulau-Florea, Alina
Cullinane, Ann
Shalabi, Haneen
Lozier, Jay
Shah, Nirali N.
PEDIATRIC BLOOD & CANCER, 2021, 68 : S196 - S197
[29] Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation.
Tuscano, J
Tedder, TF
Kehrl, JH
FASEB JOURNAL, 1996, 10 (06): : 1213 - 1213
[30] CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
Jiahua Niu
Huiying Qiu
Fang Xiang
Lin Zhu
Jun Yang
Chongmei Huang
Kun Zhou
Yin Tong
Yu Cai
Baoxia Dong
Yuan Lu
Xuedong Sun
Liping Wan
Xueying Ding
Haopeng Wang
Xianmin Song
Blood Cancer Journal, 13

← 1 2 3 4 5 →